IONS Q2 2021 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$12B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$126M-13.6% YoY

Gross Profit

$123M97.6% margin

Operating Income

-$73M-58.0% margin

Net Income

-$81M-64.3% margin

EPS (Diluted)

$-0.57

QoQ Revenue Growth

+12.7%

Cash Flow

Operating Cash Flow

-$63M

Free Cash Flow

-$69M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$2.5B

Total Liabilities

$1.9B

Stockholders' Equity

$583M

Cash & Equivalents

$565M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$126M	$146M	-13.6%
Gross Profit	$123M	$143M	-13.8%
Operating Income	-$73M	-$52M	-41.0%
Net Income	-$81M	-$26M	-215.5%

Revenue Segments

Commercial

$86M41%

Spinraza Royalties

$72M34%

Research and Development Revenue Under Collaborative Agreements

$40M19%

Product

$12M5%

Licensing and Other Royalties

$2M1%